1. Home
  2. Vol 22, No 1 (2022)
  3. Purwanto

Penerapan Modalitas Anti-PD-1/PD-L1 pada Pasien KPTN di Indonesia

Ibnu Purwanto

Abstract


Hingga saat ini tatalaksana KPTN masih belum menghasilkan peningkatan kesintasan yang memuaskan. Jika dibandingkan subtipe KPD lainnya, KPTN bersifat lebih imunogenik dengan ekspresi PD-1/PD-L1 yang lebih tinggi sehingga menjadi kandidat yang baik dalam penggunaan anti-PD-1/PD-L1. Berbagai penelitian telah menunjukan bahwa anti-PD-1/PD-L1 dapat digunakan secara efektif dalam terapi KPTN sebagai kombinasi dengan kemoterapi sistemik, baik dalam seting adjuvan maupun neoadjuvan. Tidak semua anti-PD-1/PD-L1 menunjukan manfaat yang sama dan sejauh ini pembrolizumab merupakan agen anti-PD-1/PD-L1 yang menunjukan respon paling baik pada KPTN. Telaah literatur ini bertujuan untuk merangkum bukti klinis yang ada serta membuat rekomendasi terkait penerapan agen PD-1/PD-L1 dalam manajemen pasien KPTN di Indonesia.

Keywords


breast cancer; triple negative; PD-1; PD-L1; therapy

References


Collignon J, Lousberg L, Schroeder H, Jerusalem G. Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press). 2016; 8: 93–107.

Pareja F, Geyer FC, Marchiò C, Burke KA, Weigelt B, Reis-Filho KS. Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer. 2016 Nov; 2: 16036.

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar; 26(8): 1275-81.

Purwanto I, Dwiprahasto I, Aryandono T, Mubarika S. Treatment options for Indonesian triple negative breast cancer patients: a literature review of current state and potentials for future improvement. J Med Sci. 2020;52(1):81–101.

Ai L, Chen J, Yan H, He Q, Luo P, Xu Z, et al. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy. Drug Des Devel Ther. 2020;14:3625-49.

Kwa MJ, Adams S. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. Cancer. 2018 May; 124(10): 2086-103.

Budimir N, Thomas GD, Dolina JS, Salek-Ardakani S. Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade. Cancer Immunol Res. 2021.

Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014 Apr; 2(4): 361–70.

Yoshikawa K, Ishida M, Yanai H, Tsuta K, Sekimoto M, Sugie T. Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer. PLoS One. 2021 Sep; 16(9): e0257860.

Rozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, et al. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. J Immunother Cancer. 2020 Nov; 8(2): e001558.

Boman C, Zerdes I, Mårtensson K, Bergh J, Foukakis T, Valachis A, et al. Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2021 Sep; 99: 102257.

Purwanto I, Heriyanto DS, Ghozali A, Widodo I, Dwiprahasto I, Aryandono T, et al. Overexpression of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer. World J Oncol. 2020; 11(5): 216-22.

Matikas A, Zerdes I, Lövrot J, Richard F, Sotiriou C, Bergh J. Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data. Clin Cancer Res. 2019 Sep; 25(18): 5717-26.

Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J, et al. Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. Front Oncol. 2021 Apr; 11: 56231.

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb; 382(9): 810-1.

Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020 Dec; 396(10265):1817-28.

Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021 Aug; 32(8): 994-1004.

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 Nov; 379(22): 2108-21.

Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 tria. Lancet. 2020 Oct; 396(10257): 1090-100.

Gianni L, Huang C, Egle D, Bermejo B, Zamagni C, Thill M, et al. Pathologic complete response to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. In San Antonio Breast Cancer Symposium; 2019; San Antonio. p. Abstract GS3-04.

Bachelot T, Filleron T, Bieche I, Arnedos M, Campone M, Dalenc F, et al. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. Nat Med. 2021 Feb; 27(2): 250-5.

Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, et al. Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. NPJ Breast Cancer. 2021; 7: 9.

Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019 Aug; 30(8): 1279-88.

Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Apr; 22(4): 499-511.

Zheng H, Siddharth S, Parida S, Wu X, Sharma D. Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation. Cancers (Basel). 2021 Jul; 13(13): 3357.

Cubas R, Moskalenko M, Cheung J, Yang M, McNamara E, Xiong H, et al. Chemotherapy Combines Effectively with Anti-PD-L1 Treatment and Can Augment Antitumor Responses. J Immunol. 2018 Oct; 201(8): 2273-86.

Ali HR, Glont SE, Blows FM, Provenzano E, Dawson SJ, Liu B, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol. 2015 Jul; 26(7): 1488-93.

Mori H, Kubo M, Yamaguchi R, Nishimura R, Osako T, Arima N, et al. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget. 2017 Feb; 8(9): 15584-92.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019 Jun; 25(6): 920-8.

Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, et al. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. J Natl Cancer Inst. 2021 Aug; 113(8): 1005-16.


Full Text: PDF

DOI: 10.24815/jks.v22i1.24785

Refbacks

  • There are currently no refbacks.